目的 探讨注射用甲磺酸酚妥拉明联合硝苯地平缓释片（Ⅱ）治疗妊娠期高血压的临床疗效。方法 选取2010年11月—2017年11月乐山市人民医院收治的妊娠期高血压患者76例为研究对象，利用Excel软件随机分为对照组和治疗组，每组各38例。对照组口服硝苯地平缓释片（Ⅱ），1片/次，2次/d。治疗组在对照组的基础上静脉滴注注射用甲磺酸酚妥拉明，10 mg加入到5%葡萄糖注射液250 mL中，1次/d。两组患者均连续治疗10 d。观察比较两组的妊娠结局、血压、24 h尿蛋白和血浆黏度。结果 治疗后，治疗组顺产明显高于对照组，而早产、死亡、窒息和宫内窘迫显著低于对照组，两组比较差异具有统计学意义（P < 0.05）。治疗后，两组患者收缩压和舒张压均显著下降，同组治疗前后比较差异具有统计学意义（P < 0.05）；且治疗组患者的收缩压和舒张压均明显低于对照组，两组比较差异具有统计学意义（P < 0.05）。治疗后，两组24 h尿蛋白水平均显著下降，同组治疗前后比较差异具有统计学意义（P < 0.05）；且治疗组24 h尿蛋白水平明显低于对照组，两组比较差异具有统计学意义（P < 0.05）。治疗后，两组血浆黏度均显著下降，同组治疗前后比较差异具有统计学意义（P < 0.05）；且治疗组血浆黏度明显低于对照组，两组比较差异具有统计学意义（P < 0.05）。结论 注射用甲磺酸酚妥拉明联合硝苯地平缓释片（Ⅱ）治疗妊娠期高血压具有较好的临床疗效，能降低不良妊娠结局，控制血压，降低24 h尿蛋白和血浆黏度，具有一定临床推广应用价值。

Objective To investigate the clinical efficacy of Phentolamine Mesylate for injection combined with Nifedipine Sustained-release Tablets (Ⅱ) in treatment of gestational hypertension. Methods Patients (76 cases) with gestational hypertension in the People's Hospital of Leshan from November 2010 to November 2017 were randomly divided into control and treatment groups, and each group had 38 cases. Patients in the control group were po administered with Nifedipine Sustained-release Tablets (Ⅱ), 1 tablet/time, twice daily. Patients in the treatment group were iv administered with Phentolamine Mesylate for injection on the basis of the control group, 10 mg added into 5% glucose solution 250 mL, once daily. Patients in two groups were treated for 10 d. After treatment, pregnancy outcome, blood pressure, 24 h urine protein, and plasma viscosity in two groups were compared. Results After treatment, delivery in the treatment group was significantly higher than that in the control group, but preterm birth, death, asphyxia, and intrauterine distress of fetus in the treatment group was significantly lower than those in the control group, and there was difference between two groups (P < 0.05). After treatment, the systolic and diastolic pressures in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of 24 h urine protein in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the level of 24 h urine protein in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the plasma viscosity in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the plasma viscosity in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P < 0.05). Conclusion Phentolamine Mesylate for injection combined with Nifedipine Sustained-release Tablets (Ⅱ) has clinical curative effect in treatment of gestational hypertension, can decrease the adverse pregnancy outcomes, control blood pressure, and reduce the 24 h urinary protein and plasma viscosity level, which has a certain clinical application value.